logo

For the Inventor, By the Inventor

Basel, Switzerland

Beone Medicines I Gmbh


USPTO Granted Patents = 13


Forward Citations = 0

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Zhiwei Wang (10 out of 80 patents)

silverMedal Jing Li (6 out of 152 patents)

bronzeMedal Sanjia Xu (5 out of 8 patents)

4.  Ce Wang (3 out of 61 patents)

5.  Guoliang Zhang (3 out of 23 patents)

6.  Jianzhuang Miao (3 out of 5 patents)

7.  Yunhang Guo (2 out of 25 patents)

8.  Huaqing Liu (2 out of 7 patents)

9.  Hanzi Sun (2 out of 4 patents)

10.  Gang Chen (2 out of 50 patents)

11.  Lina Gu (2 out of 3 patents)

12.  Chao Yu (1 out of 25 patents)

13.  Ye Liu (1 out of 130 patents)

14.  Hexiang Wang (1 out of 18 patents)

15.  Xiaosong Yu (1 out of 3 patents)


13 patents:

1. 12698294 - Substituted pyrazoles as sting modulators (2026-08-04),
2. 12679844 - Imidazotriazine and pyrrolopyrimidine derivatives as KRAS G12C inhibitors (2026-07-14),
3. 12673933 - Aminopyrazine compounds as HPK1 inhibitor and the use thereof (2026-07-07),
4. 12643903 - Bifunctional compounds for degradation of EGFR and related methods of use (2026-06-02),
5. 12637480 - Heterocyclic compounds as sting modulators (2026-05-26),
6. 12630552 - Inhibitors of KRAS G12C (2026-05-19),
7. 12612407 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist (2026-04-28),
8. 12606556 - TYK-2 inhibitor (2026-04-21),
9. 12583866 - Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists (2026-03-24),
10. 12521440 - Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use (2026-01-13),
11. 12516053 - Bcl-2 inhibitors (2026-01-06),
12. 12459958 - Tricyclic compounds as HPK1 inhibitor and the use thereof (2025-11-04),
13. 12454534 - Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof (2025-10-28),
Company Overview
Beone Medicines I GmbH, based in Basel, Switzerland, is focused on the development of innovative therapeutic solutions in the field of medicine. The company specializes in advancing drug discovery and development processes, particularly in the areas of oncology and rare diseases. By leveraging cutting-edge research methodologies and technologies, Beone Medicines aims to address unmet medical needs and enhance patient outcomes through its targeted therapeutic approaches.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

13 Patents

#35 in Basel

#878 in Switzerland

#45,039 in the World

Basel, CH
Basel, Switzerland

Beone Medicines I Gmbh

Forward Citations = 0

25 inventors:

goldMedal Zhiwei Wang (10 out of 80 patents)

silverMedal Jing Li (6 out of 152 patents)

bronzeMedal Sanjia Xu (5 out of 8 patents)

4.  Ce Wang (3 out of 61 patents)

5.  Guoliang Zhang (3 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Beone Medicines I Gmbh. Retrieved from https://idiyas.com/company/beone-medicines-i

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…